Gastrin I (human): A Versatile Tool for Gastric Acid Secretion Pathway Research

Introduction

Understanding the regulation of gastric acid secretion is fundamental to advancing research in gastrointestinal physiology and the pathophysiology of related disorders. Among the endogenous regulators, Gastrin I (human) stands out as a critical peptide hormone for probing the mechanisms underlying acid secretion, proton pump activation, and receptor-mediated signal transduction in the gastric mucosa. As the field increasingly turns to sophisticated in vitro models such as human pluripotent stem cell-derived organoids, the deployment of defined regulatory peptides like Gastrin I (human) becomes essential for dissecting cellular responses and signaling pathways. This article delineates the biochemical properties, core applications, and emerging research frontiers for Gastrin I (human) in gastric acid secretion pathway research, with particular attention to its role as a CCK2 receptor agonist and its value in experimental platforms modeling gastrointestinal physiology.

Biochemical Profile and Mechanism of Gastrin I (human)

Gastrin I (human) is a 17-amino-acid peptide with a molecular weight of 2098.22 Da (CAS: 10047-33-3). Endogenously, it is produced by G cells in the gastric antrum and secreted in response to dietary stimuli. Gastrin I exerts its biological effects primarily through binding to the cholecystokinin B (CCK2) receptor, a G protein-coupled receptor expressed on gastric parietal and enterochromaffin-like (ECL) cells.

Upon ligand binding, the CCK2 receptor triggers a cascade of intracellular events, including activation of phospholipase C, inositol trisphosphate (IP3) formation, and subsequent mobilization of intracellular Ca²⁺. This leads to stimulation of the H⁺/K⁺-ATPase (proton pump), culminating in increased gastric acid secretion. Notably, Gastrin I’s selective agonism of the CCK2 receptor distinguishes it from other gastrointestinal hormones and enables its use as a precise experimental modulator of gastric acid secretion pathways.

In vitro, Gastrin I (human) is supplied as a high-purity (≥98% by HPLC and MS) lyophilized white solid, insoluble in water and ethanol but readily dissolved in DMSO (≥21 mg/mL). For experimental consistency, it is recommended to store the product desiccated at -20°C and use freshly prepared solutions due to its instability in solution over time.

Gastrin I (human) as a Model Agonist in Gastric Acid Secretion Pathway Research

The unique pharmacological specificity of Gastrin I (human) for the CCK2 receptor underpins its utility in elucidating the receptor-mediated signal transduction mechanisms fundamental to gastric acid secretion. This makes the peptide invaluable in:

• Dissecting signaling pathways: Gastrin I enables precise mapping of downstream pathways following CCK2 receptor engagement, including protein kinase cascades and Ca²⁺ fluxes, which govern proton pump activation in parietal cells.
• Screening therapeutics and antagonists: By serving as a consistent agonist, it allows for reproducible assessment of candidate drug effects on acid secretion, receptor antagonism, and downstream signaling in both cell-based and tissue explant models.
• Comparative physiology studies: The conserved structure and function of Gastrin I across species facilitate cross-species analyses of gastric physiology, particularly in models that recapitulate human gastrointestinal function.

Integration with Advanced In Vitro Models: Organoids and Signal Transduction Studies

Recent advances in stem cell biology have led to the development of complex 3D organoid systems derived from human pluripotent stem cells. These intestinal organoids offer unprecedented opportunities for replicating physiological and pathological processes of the gastrointestinal tract in vitro. A pivotal study by Saito et al. (European Journal of Cell Biology, 2025) established protocols for generating human induced pluripotent stem cell (hiPSC)-derived intestinal organoids (IOs) that recapitulate the epithelial architecture, transporter expression, and metabolic activity characteristic of the human intestine.

While the focus of Saito et al. was primarily on drug absorption and metabolism, the implications for gastric acid secretion pathway research are significant. The ability to differentiate IOs into mature epithelial lineages—including enteroendocrine cells that endogenously express gastrin and related peptides—provides a physiologically relevant platform for studying CCK2 receptor signaling and its downstream effects. Exogenous application of Gastrin I (human) in such systems could enable:

• Analysis of receptor-specific responses: Evaluating the differential activation of CCK2 receptor pathways in human versus animal-derived organoids.
• Modeling gastrointestinal disorder mechanisms: Investigating aberrant acid secretion or altered signal transduction in disease-mimicking organoid cultures.
• Testing pharmacological interventions: Assessing the efficacy of proton pump inhibitors, CCK2 receptor antagonists, or other modulators in a human-relevant context.

These approaches extend the utility of Gastrin I (human) beyond classical cell lines, allowing for multidimensional interrogation of gastric acid secretion regulation in health and disease.

Applications in Gastrointestinal Disorder Research

The tight regulation of gastric acid secretion is central to gastrointestinal homeostasis. Dysregulation contributes to a spectrum of disorders, including peptic ulcer disease, gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and gastric neoplasia. The role of Gastrin I (human) as a research tool is multi-faceted:

• Pathway elucidation: By selectively stimulating the CCK2 receptor, researchers can delineate the molecular abnormalities underlying hypergastrinemia-associated diseases or hypoacidity states.
• Pharmacological modeling: Gastrin I facilitates the evaluation of candidate compounds targeting the CCK2 receptor, proton pumps, or related signaling molecules, providing mechanistic insights into their modes of action.
• Biomarker discovery: Its use in controlled in vitro systems allows for the identification of downstream effectors or secreted factors that may serve as biomarkers or therapeutic targets in gastrointestinal disorder research.

Moreover, integration of Gastrin I (human) with organoid-based disease models can provide a more predictive preclinical platform, especially for disorders where species differences limit the translational relevance of animal models, as highlighted by Saito et al. (2025).

Experimental Considerations and Best Practices

To ensure experimental rigor when utilizing Gastrin I (human), researchers should consider the following technical guidelines:

• Solubility: The peptide is insoluble in water and ethanol but dissolves effectively in DMSO at concentrations ≥21 mg/mL. Solutions should be freshly prepared and used promptly to prevent degradation.
• Storage: Lyophilized peptide should be kept desiccated at -20°C. Reconstituted solutions are not suitable for long-term storage.
• Concentration range: Dose-response studies are recommended to define the optimal concentration for receptor activation in the chosen model system, as sensitivity may differ between conventional cell lines and advanced 3D organoid cultures.
• Controls: Parallel assays using CCK2 receptor antagonists or proton pump inhibitors should be included to validate pathway specificity and dissect off-target effects.

Future Directions: Expanding the Toolkit for Gastrointestinal Physiology Studies

The convergence of high-purity synthetic peptides like Gastrin I (human) and next-generation in vitro models, such as hiPSC-derived intestinal organoids, is accelerating the pace of discovery in gastric acid secretion pathway research. Future studies could leverage CRISPR-based genome editing to create organoid lines with altered CCK2 receptor expression, providing deeper insights into receptor-mediated signal transduction mechanisms.

Additionally, multi-omics approaches (transcriptomics, proteomics, and metabolomics) in peptide-stimulated organoids may uncover novel regulatory nodes linking gastrin signaling to epithelial homeostasis, stem cell behavior, and disease susceptibility. Such integrative strategies promise to refine our understanding of both normal physiology and the molecular etiology of gastrointestinal disorders.

Conclusion

Gastrin I (human) remains an indispensable reagent for researchers investigating the intricacies of gastric acid secretion, CCK2 receptor signaling, and gastrointestinal physiology. Its specificity, purity, and compatibility with advanced in vitro models position it at the forefront of contemporary gastrointestinal disorder research. By enabling rigorous dissection of proton pump activation and receptor-mediated signal transduction, Gastrin I (human) supports both fundamental discovery and translational efforts aimed at improving gastrointestinal health.

Comparison with Previous Literature

Unlike the study by Saito et al. (2025), which focused on the generation and pharmacokinetic profiling of hiPSC-derived intestinal organoids, this article provides a dedicated exploration of Gastrin I (human) as a biochemical tool for dissecting the gastric acid secretion pathway and CCK2 receptor signaling in both traditional and cutting-edge in vitro models. By integrating technical guidance on peptide handling with emerging research applications in disease modeling and drug screening, this piece extends the discussion beyond organoid development to encompass the practical and mechanistic considerations essential for advancing gastrointestinal physiology studies.